 |
 |
 |
 |
 |
 |
- Follow Akebia:
RSS
The Latest News from Akebia
4.5.12
Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548
1.9.12
Akebia Draws Down $4.1 Million Series B Financing Tranche
11.21.11
Akebia Initiates Phase 1 Study of First-In-Class HPTPβ Inhibitor for Diabetic Macular Edema
11.15.11
Akebia Therapeutics Announces Presentation of Clinical Data at Kidney Week 2011
6.23.11
Akebia Announces Initiation of Phase 2a Dose Range Finding Study of AKB-6548 for Anemia
5.3.11
Akebia Announces Successful Completion of Phase 2a Pilot Study of AKB-6548 For Anemia
513.985.1920, info@akebia.com
9987 Carver Road, Suite 420, Cincinnati, OH, 45242
Privacy Policy | Terms and Conditions
